SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

COGT

Cogent Biosciences, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor upcoming IND filing for CGT1263 and further clinical updates on CGT4255 combinations. Despite recent insider selling of $242.6M, the data readout supports long-term pipeline optionality and could attract partnership interest, especially in the competitive KRAS and HER2+ brain mets spaces.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$37.25
T+0 close · Apr 17, 2026 · via day close
Latest settled
+3.38%
T+60 · $38.51
Vs SPY
−2.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $37.25entry
  2. T+1 · 7mo ago −0.67%α −0.48% · $37.00
  3. T+5 · 7mo ago −1.18%α −1.74% · $36.81
  4. T+20 · 6mo ago −8.21%α −13.59% · $34.19
  5. T+60 · 4mo ago +3.38%α −2.76% · $38.51
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cogent Biosciences presented preclinical data at AACR 2026 for two pipeline candidates: CGT1263, a pan-KRAS(ON) inhibitor with potential differentiation in skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor showing synergy with HER2 ADCs in resistant patients. IND submission for CGT1263 is expected later this year, while Phase 1 trials for CGT4255 are ongoing.

Key Facts

  • Presented preclinical data for CGT1263, a pan-KRAS(ON) inhibitor with >500x selectivity for mutant KRAS over HRAS/NRAS, potentially reducing skin toxicity seen with multi-RAS inhibitors.
  • CGT1263 shows sustained pERK inhibition and robust antitumor activity in preclinical models, with limited skin suppression suggesting a wider therapeutic window.
  • Presented data for CGT4255, a brain-penetrant ErbB2 inhibitor with >100-fold selectivity over EGFR, active against key HER2 mutations and showing synergistic effects when combined with HER2 ADCs like T-DXd.
  • IND submission for CGT1263 expected later in 2026; Phase 1 trial for CGT4255 is already ongoing.
  • Management highlighted potential for 'multiple blockbuster programs' in the pipeline.

Financial Impact

Preclinical data enhances pipeline value; no immediate revenue impact but increases probability of clinical success and future monetization.

pipeline valueR&D valuationmarket sentiment

Risk Factors

  • Preclinical data may not translate to clinical efficacy in humans.
  • High valuation ($5.9B market cap) is sensitive to clinical setbacks or dilution risk.
  • Recent insider selling raises concerns about near-term sentiment despite positive data.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276106

Track record

13 reports on COGT

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
  4. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  5. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  6. Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  7. Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  8. Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  9. May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
  10. May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026